Enveda Closes $311M Series E at $2B Valuation to Push AI-Discovered Natural Medicines Into Late-Stage Trials

Colorado-based Enveda closed a $311M Series E led by Catalio Capital Management at a $2B valuation - double its mark from 12 months ago - taking total funding past $845M. New investors include Durable Capital, ICONIQ, Lightspeed, T. Rowe Price and Digitalis Ventures, joining Baillie Gifford, Premji Invest and Lux Capital. Proceeds will push ENV-294 (atopic dermatitis) and ENV-308 (metabolic health) into later-stage trials after positive early readouts from its PRISM natural-product AI platform.